Vion's TAPET Organisms Demonstrate Reduced Virulence, Increased Safety While Retaining Ability To Specifically Target Tumors

December 29, 1998

Genetically Modified Salmonella Lack Ability to Induce TNF-Alpha and Cause Sepsis According to Nature Biotechnology Publication

NEW HAVEN, CT (December 29, 1998): New research demonstrates that genetic modification of a cell wall component of tumor-targeting Salmonella bacteria can greatly reduce the bacteria's potential for virulence and ability to cause septic shock, announced Vion Pharmaceuticals, Inc. (Nasdaq: VION). Vion is developing the modified bacteria, the heart of the company's TAPET technology, as vectors for the targeted, systemic delivery of anti-cancer agents to tumors throughout the body.

A publication detailing the research, entitled "Lipid A mutant Salmonella with suppressed virulence and TNF-alpha induction retain tumor-targeting in vivo," will appear in the January issue of the journal Nature Biotechnology. The article is authored by scientists at Vion and their collaborators at Yale University School of Medicine; Texas A&M University, College of Veterinary Medicine; and the University of Washington Health Sciences Center.

Vion researchers and their collaborators have previously reported the development of Salmonella that specifically target tumors over normal tissues. However the clinical utility of such bacteria was potentially limited by the ability of lipid A in the bacteria's cell walls to elicit the production of TNF-alpha and trigger septic shock. Now the researchers have shown that a disruption of the Salmonella msbB gene involved in the production of lipid A reduces, by 10,000 fold, the ability of the bacteria's lipid to induce TNF-alpha and cause death in animal models. At the same time, the msbB-minus Salmonella retain their tumor-targeting properties, exhibiting the ability to accumulate in tumors at ratios in excess of 1000:1 compared with normal tissues.

"Administration of these modified bacteria to mice bearing melanoma tumors results in tumors that are less than six percent the size of tumors in untreated control animals," said David Bermudes, Ph.D., associate director of biology at Vion and an author of the publication. "Thus, the anti-tumor activity that we previously demonstrated using tumor-targeting bacteria with normal lipid A is retained. At the same time, the modified bacteria's potential for causing septic shock is essentially eliminated." Septic shock from bacterial infection can produce a variety of potentially life-threatening complications.

"Our results with msbB-minus Salmonella in both laboratory and animal models are consistent with the idea that these organisms should be safe for use in humans," Dr. Bermudes continued. "In addition the msbB-minus bacteria that we are developing as anticancer vectors remain fully sensitive to a wide range of antibiotics, adding an additional level of safety and control." Vion expects to begin human clinical safety studies using the modified TAPET organisms in the first quarter of 1999. Ultimately, the company plans to develop the TAPET bacteria as systemically administered vectors for the selective delivery of anticancer agents and pro-drug converting enzymes to tumors.

Additional Research Results
The researchers tested the msbB-minus bacteria in several cell culture and animal models of TNF-alpha induction and septic shock, comparing results with the modified organisms to those elicited by wild-type Salmonella. Their reported findings included:

• Purified lipopolysaccharide (LPS) from the msbB-minus mutant bacteria showed at least a 10,000-fold reduction in the induction of TNF-alpha by human monocytes compared to LPS from wild-type organisms.

• The ability of live msbB-minus bacteria to elicit TNF-alpha in animals was significantly reduced compared to wild type organisms. In a standard swine model of septic shock, msbB-minus bacteria induced only 14 percent of the TNF-alpha induced by wild type organisms.

• Ninety minutes after injection, respiration was significantly increased in swine injected with wild-type bacteria compared to controls, but not in swine injected with the msbB-minus bacteria.

• The msbB-minus bacteria exhibited reduced survival in mouse macrophages compared to wild-type bacteria. This implies that, except in tumors where bacteria are sequestered from the immune system, the TAPET organisms will be eliminated by the immune system.

• Injection of the mutated Salmonella into mice and swine caused no deaths, while administration of wild-type bacteria produced mortality in all of the mice within four days and 90 percent of the treated swine within 28 days.

Vion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of novel products and technologies for the treatment of cancer and viral diseases. The company has an extensive research and development pipeline focused on five principal projects: Promycin (porfiromycin), a hypoxic cancer cell therapy currently undergoing Phase III clinical testing; TAPET, the company's platform cancer treatment technology; Triapine, a ribonucleotide reductase inhibitor currently in a Phase I clinical trial; Beta-L-FD4C, a novel nucleoside analog for the treatment of viral diseases; and arylsufonyl hydrazine prodrugs, for the treatment of cancer. The company has licensed its non-core MELASYN(synthetic melanin) technology to San-Mar Laboratories, who plans to market its first OTC cosmeceutical preparations for vitiligo through the company's subsidiary, Vitiligo Solution, Inc. For additional information on Vion and its research and product development programs, visit the company's Internet web site at http://www.vionpharm.com.

Statements included in this press release which are not historical in nature are forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements regarding the Vion Pharmaceuticals future business prospects, plans, objectives, expectations and intentions are subject to certain risks, uncertainties and other factors that could cause actual results to differ materially from those projected or suggested in the forward-looking statements, including, but not limited to those contained in the Vion Pharmaceuticals Registration Statement filed on Form S-3 (file no. 333-37941).
-end-
John Spears
President and CEO
Vion Pharmaceuticals, Inc.
(203) 498-4210
Email: vioninfo@vionpharm.com

Joan Kureczka
J. Kureczka Associates
(415) 821-2413
Email: JKureczka@aol.com



Kureczka/Martin Associates

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.